ACSL4 and hepatocellular carcinoma: Interestingly, expression of the ferroptosis mediator ACSL4 was reported to be higher in those HCC patients that showed responses to treatment with sorafenib [31], pointing towards a potential use of ACSL4 as predictive biomarker.